B cell Activating Factor/TNFSF13B (Human)

Product Description

B cell Activating Factor/TNFSF13B (Human, Recombinant)
Catalog number: B2010293
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure B cell Activating Factor/TNFSF13B (Human, Recombinant) expressed in CHO . This protein acts as a member of the tumor necrosis factor (TNF) family with an essential role in peripheral B-cell homeostasis.
Storage: -20C
Keywords: rHuBAFF/TNFSF13B; BLYS; TALL1; THANK; ZTNF4; TALL-1; TNFSF20
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Ferraccioli G, Gremese E. B cell activating factor (BAFF) and BAFF receptors:
fakes and facts. Clin Exp Immunol. 2017 Dec;190(3):291-292.

2: Wang X, Liang KD, Zhang JA, Liu GB, Chen Z, Chen C, Zhuang ZG, Liu YQ, Luo
HL, Li RX, Zheng BY, Xu JF. Increased B cell activating factor is associated
with B cell class switching in patients with tuberculous pleural effusion. Mol
Med Rep. 2018 Aug;18(2):1704-1709.

3: Smulski CR, Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival.
Front Immunol. 2018 Oct 8;9:2285.

4: Battaglino RA, Nguyen N, Summers M, Morse LR. B Cell-Activating_Factor Is
Associated with Testosterone and Smoking Status in Non-Ambulatory Men with
Chronic Spinal Cord Injury. J Neurotrauma. 2019 Dec 15;36(24):3332-3337.

5: Kościelska-Kasprzak K, Bartoszek D, Myszka M, Kamińska D, Boratyńska M,
Krajewska M, Klinger M. B Cell Activating Factor (BAFF) in Long-term Kidney
Transplant Recipients Is Not a Prognostic Marker for Allograft Dysfunction or
Survival. Transplant Proc. 2018 Jul-Aug;50(6):1750-1754.

6: Omachi S, Fujii W, Azuma N, Morimoto A, Sanjoba C, Matsumoto Y, Goto Y.
B-cell_activating factor deficiency suppresses splenomegaly during Leishmania
donovani infection. Biochem Biophys Res Commun. 2017 Aug 5;489(4):528-533.

7: Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren
syndrome. Nat Rev Rheumatol. 2018 Mar;14(3):133-145.

8: Wang XZ, Wan Z, Xue WJ, Zheng J, Li Y, Ding CG. B-Cell_Activating Factor
Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-
Up Study. Front Immunol. 2019 May 15;10:1046.

9: McClure M, Gopaluni S, Jayne D, Jones R. B cell therapy in ANCA-associated
vasculitis: current and emerging treatment options. Nat Rev Rheumatol. 2018
Oct;14(10):580-591. doi: 10.1038/s41584-018-0065-x. Epub 2018 Aug 14. Erratum
in: Nat Rev Rheumatol. 2018 Dec;14(12):741.
10: Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M,
Moutsopoulos HM, Mavragani CP. B-cell activating factor and related genetic
variants in lupus related atherosclerosis. J Autoimmun. 2018 Aug;92:87-92.

Products Related to B cell Activating Factor/TNFSF13B (Human, Recombinant) : Proteins